RecruitingPhase 3NCT06230224
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Regeneron Pharmaceuticals
- Principal Investigator
- Clinical Trial ManagementRegeneron Pharmaceuticals
- Intervention
- Odronextamab(drug)
- Enrollment
- 216 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (30)
- Hospital Aleman, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
- Hospital Britanico de Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
- Instituto Alexander Fleming, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
- Fundaleu - Fundacion Para Combatir La Leucemia, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
- Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
- Hospital Italiano de La Plata, La Plata, Buenos Aires, Argentina
- Sanatorio Allende, Córdoba, Argentina
- Hospital Privado Universitario de Cordoba, Córdoba, Argentina
- Liverpool Hospital, Liverpool, New South Wales, Australia
- Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
- Royal Hobart Hospital, Hobart, Tasmania, Australia
- Olivia Newton John Cancer Wellness & Research Centre, Heidelberg, Victoria, Australia
- Hospital Santa Izabel - Santa Casa de Misericordia da Bahia, Salvador, Estado de Bahia, Brazil
- Hospital Sao Rafael, Salvador, Estado de Bahia, Brazil
- Ensino e Terapia de Inovacao Clinica Amo (Etica), Salvador, Estado de Bahia, Brazil
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06230224 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic